Breaking News Instant updates and real-time market news.

ADUS

Addus HomeCare

$75.66

1.08 (1.45%)

, AMED

Amedisys

$132.83

3.85 (2.99%)

04:55
12/13/18
12/13
04:55
12/13/18
04:55

Stephens to hold a plane trip

Healthcare Services Investor Plane Trip will begin on December 11 in Austin, TX and end in Nashville, TN on December 11-13.

ADUS

Addus HomeCare

$75.66

1.08 (1.45%)

AMED

Amedisys

$132.83

3.85 (2.99%)

BKD

Brookdale Senior Living

$8.48

-0.01 (-0.12%)

EHC

Encompass Health

$73.37

0.79 (1.09%)

LHCG

LHC Group

$103.42

1.96 (1.93%)

ADUS Addus HomeCare
$75.66

1.08 (1.45%)

11/07/18
OPCO
11/07/18
NO CHANGE
Target $80
OPCO
Outperform
Addus HomeCare price target raised to $80 from $72 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Addus HomeCare to $80 from $72 following quarterly results. The analyst believes the company continues to perform well operationally, and its rapid M&A pace and balance sheet changes are going to help results take another step forward. He reiterates an Outperform rating on the shares.
08/21/18
JEFF
08/21/18
INITIATION
Target $75
JEFF
Buy
Addus HomeCare initiated with a Buy at Jefferies
Jefferies analyst Brian Tanquilut initiated Addus HomeCare with a Buy rating and $75 price target, as he believes the continued rise in demand for personal care services should allow the company to sustain its mid-single-digit organic growth rate. The company's recent capital raise signals an intent to "aggressively" pursue growth-boosting acquisitions while changes to Medicare Advantage regulations will create a significant growth opportunity, added Tanquilut.
09/12/18
CANT
09/12/18
INITIATION
CANT
Overweight
Addus HomeCare initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph France initiated Addus HomeCare with an Overweight and $77 price target.
10/08/18
RBCM
10/08/18
INITIATION
Target $81
RBCM
Outperform
Addus HomeCare initiated with an Outperform at RBC Capital
RBC Capital analyst Frank Morgan initiated Addus HomeCare with an Outperform rating and a price target of $81, saying he sees a "strong opportunity for growth" in the personal care and hospice sectors. The analyst expects the company to benefit from further consolidation in the industry and sees upside in its revenue and EBITDA prospects as a result. With small cap growth opportunities in health care becoming a "rarity", Morgan tells investors in his research note, he sees Addus HomeCame potential as compelling based on its "simple" business model of "high touch / low tech with heavy focus on logistics".
AMED Amedisys
$132.83

3.85 (2.99%)

11/15/18
UBSW
11/15/18
INITIATION
UBSW
HCA Healthcare, Encompass Health, Universal Health initiated with Buy at UBS
UBS analyst Whit Mayo launched coverage of Healthcare Facilities with a broader research note titled "Navigating an Evolving Landscape - Who Will Be Left?". The analyst is most bullish on stocks that "discount the perceived secular sector headwinds" such as Buy-rated HCA Healthcare (HCA), Encompass Health (EHC), and Universal Health (UHS), adding that investors also under-appreciate the accelerating free-cash flow profiles of these companies. Mayo differentiates HCA Healthcare based on its 0% correlation in national hospital utilization trends against public results. The analyst is also bullish on LHC Group (LHCG), stating that its same-property admission growth projections are higher than the rest. Mayo rates Community Health Systems (CYH), DaVita (DVA), and Mednax (MD) at a Sell with a bearish view of dialysis, births, and inpatient surgery end-markets. The analyst sees Community Health Systems same-property volume trend at a relatively low rate. Mayo also gives Acadia (ACHC), Amedisys (AMED), Surgery Partners (SGRY), and Tenet (THC) a Neutral rating as part of this research note based on their relative valuation as a factor of same-property volume growth.
11/15/18
UBSW
11/15/18
INITIATION
Target $126
UBSW
Neutral
Amedisys initiated with a Neutral at UBS
UBS analyst Whit Mayo initiated Amedisys with a Neutral rating and a price target of $126.
10/30/18
10/30/18
UPGRADE
Target $125

Buy
Amedisys upgraded to Buy after 'beat and raise' report at Benchmark
As previously reported, Benchmark analyst Bill Sutherland upgraded Amedisys to Buy from Hold after the company posted what he called "another strong beat" in Q3 and lifted its full year 2018 guidance for a second time. While the stock is down nearly 30% from recent highs, the intermediate outlook has actually improved, Sutherland tells investors. He also contends that Amedisys' "growing appeal to a financial or strategic buyer" supports a premium valuation. Sutherland set a $125 price target on Amedisys shares.
10/30/18
JEFF
10/30/18
NO CHANGE
Target $140
JEFF
Buy
Amedisys pullback brings good entry point, says Jefferies
Jefferies analyst Brian Tanquilut remains bullish on Amedisys following the company's Q3 results and believes the recent share pullback provides a good entry point. The upside in the quarter underscores continued strength of the company's fundamentals, Tanquilut tells investors in a post-earnings research note. He believes the Amedisys is "poised to deliver robust earnings growth in 2019 and beyond," driven by organic acceleration in both the Medicare and Medicare Advantage businesses and management's disciplined capital deployment strategy. Tanquilut keeps a Buy rating on the shares with a $140 price target.
BKD Brookdale Senior Living
$8.48

-0.01 (-0.12%)

04/13/18
JMPS
04/13/18
NO CHANGE
Target $9
JMPS
Outperform
Brookdale Senior Living price target lowered to $9 from $16 at JMP Securities
JMP Securities analyst Peter Martin previously valued Brookdale Senior Living on an NAV basis given the expectation of a sale at the conclusion of its strategic alternatives process. While he agrees with the board's decision not to sell the company at depressed levels, he now thinks the board needs to take ownership and that at least three of the four longest tenured board members should resign. He believes 2018 will be another "transitional year" and that weak 2018 guidance is coming and would be patient on an entry point. Martin lowered his price target on Brookdale to $9 from $16, but keeps an Outperform rating on the shares.
10/11/18
SPHN
10/11/18
NO CHANGE
SPHN
Stephens says home health final rule looking like draft would weigh on providers
Stephens analyst Dana Hambly said he expects the final rule for home health reimbursement to be released by CMS in the first week of November. He is concerned that if the final rule looks similar to the draft rule, particularly regarding behavioral assumptions, it would weigh on home health stocks. For-profit, urban providers with higher percentages of therapy visits are estimated to take the largest cuts under a Patient Driven Groupings Model for reimbursement, said Hambly, who sees the impact being largest for Brookdale Senior Living (BKD) and Humana's (HUM) Kindred at Home. Others that may be impacted include Amedisys (AMED), Encompass Health (EHC), Ensign Group (ENSG) and LHC Group (LHCG).
04/30/18
BMOC
04/30/18
UPGRADE
Target $53
BMOC
Market Perform
Ventas upgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital John Kim upgraded Ventas (VTR) to Market Perform from Underperform and raised his price target to $53 from $51. Kim cites a more attractive valuation after the stock price came down another 19% in 2018. The analyst also notes that the extension of Ventas' master lease with Brookdale (BKD) "addresses a major 2019 expiration" and buys time to deal with non-performing assets while also reducing the possibility of a dividend cut in the short term.
06/27/18
MUFG
06/27/18
NO CHANGE
Target $62
MUFG
Overweight
Welltower price target raised to $62 from $58 at MUFG
MUFG analyst Karin Ford raised her price target on Welltower (WELL) to $62 and kept her Outperform rating, citing the company's progress in restructuring over half of the assisted and independent living portfolio operated by Brookdale Senior Living (BKD). The analyst claims that Welltower achieved favorable pricing on its purchases and sales in the transition, adding that she is positive on the company generating $91M in cash while reducing its exposure to a "troubled operator".
EHC Encompass Health
$73.37

0.79 (1.09%)

11/15/18
UBSW
11/15/18
INITIATION
Target $86
UBSW
Buy
Encompass Health initiated with a Buy at UBS
UBS analyst Whit Mayo initiated Encompass Health with a Buy rating and a price target of $86.
07/26/18
07/26/18
UPGRADE
Target $87

Overweight
Encompass Health upgraded to Overweight on top-line growth potential at Piper Jaffray
As previously reported, Piper Jaffray analyst Sarah James upgraded Encompass Health to Overweight from Neutral and raised her price target on the stock to $87 from $68 following her deep dive into top-line growth opportunities and rate risk. Noting that Encompass Health is her top pick within the facility space, the analyst says its strong balance sheet gives it the opportunity to meaningfully move top-line growth through M&A. Further, James sees potential for the HH segment to increase 43% through strategically placed assets and higher collaboration rates.
LHCG LHC Group
$103.42

1.96 (1.93%)

10/26/18
CHLM
10/26/18
DOWNGRADE
Target $92
CHLM
Hold
LHC Group downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Kevin Ellich downgraded LHC Group to Hold from Buy and lowered his price target to $92 from $99, telling investors in a research note that he believes uncertainty related to the potential rate cut in 2020 from Medicare's proposed Patient-Driven Groupings Model will remain an overhang on shares. While the final 2019 Medicare Home Health rule should be released in the coming days, the analyst does not expect any major changes from the proposed rule and uncertainty related to PDGM will likely keep shares of LHC Group range-bound in the near-term, especially with the stock trading at a hefty premium to its historical averages. Further, Ellich says that while he expects "solid" Q3 results and believe the integration of Almost Family is likely going well, he thinks guidance will be maintained and that Q4 consensus EPS appears "off due to the sharp increase in share count attributable to the Almost Family deal."
11/15/18
UBSW
11/15/18
INITIATION
Target $109
UBSW
Buy
LHC Group initiated with a Buy at UBS
UBS analyst Whit Mayo initiated LHC Group with a Buy rating and a price target of $109.
11/01/18
WBLR
11/01/18
NO CHANGE
WBLR
Outperform
LHC Group shares could see pressure ahead of call, says William Blair
While LHC Group's organic growth trends were strong in Q3, "this was not a clean quarter," William Blair analyst Matt Larew tells investors in a post-earnings research note.The sales miss and "disconnect from expectations," which were looking for a beat-and-raise quarter, could pressure the stock ahead of today's earnings conference call, says Larew. The analyst adds that LHC's earnings release came less than an hour after the Centers for Medicare & Medicaid Services released the final 2019 home health rule. Though this looks to be largely in line with expectations, Larew contends. He keeps an Outperform rating on shares of LHC Group.

TODAY'S FREE FLY STORIES

KNX

Knight-Swift

$36.05

-0.065 (-0.18%)

09:20
10/15/19
10/15
09:20
10/15/19
09:20
Earnings
Breaking Earnings news story on Knight-Swift »

Knight-Swift cuts Q3 adj.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RETA

Reata Pharmaceuticals

$100.37

4.57 (4.77%)

09:20
10/15/19
10/15
09:20
10/15/19
09:20
Recommendations
Reata Pharmaceuticals analyst commentary  »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$119.05

-2.55 (-2.10%)

, AAPL

Apple

$235.87

-0.34 (-0.14%)

09:20
10/15/19
10/15
09:20
10/15/19
09:20
Hot Stocks
Apple TV app, Apple TV+ coming to Roku platform »

Roku (ROKU) announced the…

ROKU

Roku

$119.05

-2.55 (-2.10%)

AAPL

Apple

$235.87

-0.34 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Nov

ABEO

Abeona Therapeutics

$2.18

-0.05 (-2.24%)

09:19
10/15/19
10/15
09:19
10/15/19
09:19
Hot Stocks
Abeona announces publication of long-term data from Phase 1/2a trial of EB-101 »

Abeona Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTEK

Tetra Tech

$84.87

-0.735 (-0.86%)

09:18
10/15/19
10/15
09:18
10/15/19
09:18
Hot Stocks
Tetra Tech awarded $85M DFID contract for LINKS program in Nigeria »

Tetra Tech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
10/15/19
10/15
09:18
10/15/19
09:18
Options
Overnight activity included 213 trades in SPX and 79 trades in VIX »

213 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

G

Genpact

$38.15

-0.27 (-0.70%)

09:17
10/15/19
10/15
09:17
10/15/19
09:17
Hot Stocks
Genpact announces definitive agreement to acquire Rightpoint »

Genpact announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 11

    Nov

ADBE

Adobe

$277.79

-0.29 (-0.10%)

09:17
10/15/19
10/15
09:17
10/15/19
09:17
Initiation
Adobe initiated  »

Adobe initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 04

    Nov

CMTL

Comtech

$30.87

-0.27 (-0.87%)

09:16
10/15/19
10/15
09:16
10/15/19
09:16
Hot Stocks
Comtech awarded maximum $98.6M Army contract for SATCOM terminals »

Comtech announced, that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
10/15/19
10/15
09:15
10/15/19
09:15
General news
U.S. equities are firmer »

U.S. equities are firmer,…

SFIX

Stitch Fix

$21.21

-0.62 (-2.84%)

09:14
10/15/19
10/15
09:14
10/15/19
09:14
Initiation
Stitch Fix initiated  »

Stitch Fix started with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SNAP

Snap

$13.76

-0.39 (-2.76%)

, TWTR

Twitter

$39.77

-0.59 (-1.46%)

09:14
10/15/19
10/15
09:14
10/15/19
09:14
Upgrade
Snap, Twitter rating change  »

Snap upgraded to Buy from…

SNAP

Snap

$13.76

-0.39 (-2.76%)

TWTR

Twitter

$39.77

-0.59 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

LVGO

Livongo Health

$18.44

0.74 (4.18%)

09:13
10/15/19
10/15
09:13
10/15/19
09:13
Hot Stocks
Livongo Health announced partnership with VSP Vision Care »

Livongo Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BAESY

BAE Systems

$0.00

(0.00%)

09:12
10/15/19
10/15
09:12
10/15/19
09:12
Hot Stocks
BAE Systems awarded $437M Army task order to provide open source support »

The U.S. Army has awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GNBT

Generex

$0.00

(0.00%)

09:12
10/15/19
10/15
09:12
10/15/19
09:12
Hot Stocks
Generex announces merger for public trading of NuGenerex Immuno-Oncology »

Generex Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 25

    Oct

UNH

UnitedHealth

$220.32

-1.69 (-0.76%)

09:11
10/15/19
10/15
09:11
10/15/19
09:11
Earnings
UnitedHealth sees FY20 adj. EPS up near low-end of 13%-16% range »

Guidance provided during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

CVNA

Carvana

$74.34

2.06 (2.85%)

09:11
10/15/19
10/15
09:11
10/15/19
09:11
Recommendations
Carvana analyst commentary  »

Carvana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PD

PagerDuty

$26.45

0.27 (1.03%)

09:11
10/15/19
10/15
09:11
10/15/19
09:11
Initiation
PagerDuty initiated  »

PagerDuty started with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSK

Alaska Communications

$1.65

-0.015 (-0.90%)

09:10
10/15/19
10/15
09:10
10/15/19
09:10
Hot Stocks
Alaska Communications appoints William Bishop as CEO »

TeAlaska Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
10/15/19
10/15
09:10
10/15/19
09:10
General news
U.S. repo rate opened at 2.04% »

U.S. repo rate opened at…

MRCY

Mercury Systems

$75.11

-0.61 (-0.81%)

09:09
10/15/19
10/15
09:09
10/15/19
09:09
Hot Stocks
Mercury Systems announces $15M capital investment in microelectronics business »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

USAT

USA Technologies

$0.00

(0.00%)

09:08
10/15/19
10/15
09:08
10/15/19
09:08
Initiation
USA Technologies initiated  »

William Blair resumes USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDFN

Redfin

$16.21

-0.225 (-1.37%)

09:07
10/15/19
10/15
09:07
10/15/19
09:07
Recommendations
Redfin analyst commentary  »

Redfin listings share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

SEEL

Seelos Therapeutics

$0.88

0.0036 (0.41%)

09:06
10/15/19
10/15
09:06
10/15/19
09:06
Hot Stocks
Seelos Therapeutics names Scott Applebaum lead strategic regulatory consultant »

Seelos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$8.35

-0.085 (-1.01%)

09:05
10/15/19
10/15
09:05
10/15/19
09:05
Hot Stocks
Ericsson and Xtreme Enterprises announce partnership »

Ericsson and Xtreme…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.